Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Harrow Inc HROW

Healthcare Drug Manufacturers - Specialty & Generic
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC... see more

Current News (NDAQ:HROW)

Harrow to Present at Two Investor Conferences in December

GlobeNewswire November 24, 2025

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

GlobeNewswire November 18, 2025

Harrow Announces Third Quarter 2025 Financial Results

GlobeNewswire November 10, 2025

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

GlobeNewswire October 27, 2025

ImprimisRx Announces Leadership Changes

GlobeNewswire October 6, 2025

Harrow to Acquire Melt Pharmaceuticals

GlobeNewswire September 26, 2025

Harrow Launches Harrow Access for All (HAFA)

GlobeNewswire September 25, 2025

Harrow Announces Agenda and Speakers for Investor & Analyst Day

GlobeNewswire September 15, 2025

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

GlobeNewswire September 8, 2025
View More News ››

Opinion & Analysis (NDAQ:HROW)

Imprimis: Priming the Pumps for a Big 2019

Streetwise Reports November 16, 2018
View More Opinion ››

Bullboard Posts (NDAQ:HROW)

Buy buddy buy.

This stock is signalling a continuing uptrend for it already this morning
coolfooldumbguy - March 28, 2025

HARROW INC: ENVISIONING A BRIGHT FUTURE

$HROW   Excited to share an article about Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company engaged in the...
AviseAnalytics - June 20, 2024
View more Bullboard ››

FPX Nickel Corp.

FPX Nickel Corp.

FPX Nickel Corp., a junior nickel mining company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts